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| INTRODUCTION
Malignancy is a strong risk factor for venous thromboembolism (VTE), shown to be associated with 20%-30% of incident VTE in population studies. 1 Cancer patients have a four-to seven-fold increased risk of VTE and a two-fold increased risk of major hemorrhage on anticoagulation when compared with patients without cancer, 2 and therefore, VTE is the second leading cause of death in the cancer population, right behind cancer itself. 3 VTE and its treatment could impact the quality of life in cancer patients, delay cancer treatment, and have complications including recurrent VTE and/or bleeding. Therefore, the optimal prevention and treatment of VTE are crucial components of patient care in this population.
Low-molecular-weight heparin (LMWH), when compared with warfarin, has been shown to reduce the risk of recurrent VTE in patients with cancer-associated thrombosis (CAT), 4 and is therefore the standard treatment for acute CAT for the past 15 years. However, the high cost and significant lifestyle burden associated with LMWH have led many clinicians and investigators to wonder whether the direct oral anticoagulants (DOACs) might be a better choice for primary and/or secondary VTE prevention in patients with cancer.
Here we review literature on important topics in the prevention and treatment of CAT. Our management recommendations are based on available evidence whenever possible. For clinical situations in which there is no high-quality evidence, we provide management suggestions that are based on our experience and opinion.
| PATHOGENESIS OF CANCER-ASSOCIATED THROMBOSIS
Multiple mechanisms of CAT have been identified, which could vary depending on the type of malignancy. A recent review has summarized this topic in detail. 5 Traditionally, CAT is thought to represent the intersection of the "Virchow's triad" with chronic disseminated intravascular coagulation (DIC) from malignancy, venous stasis from central venous catheter placement, and endothelial injury from antineoplastic chemotherapy. 6 More recent translational research suggests that the vascular microenvironment, including tissue factor, platelets, and neutrophils, explains a great deal of the prothrombotic tendencies.
Tumor derived tissue factor (TF) and TF-positive microparticles (MPs), especially those from pancreatic cancer cells, can enhance the development of VTE in vivo. 7 Retrospective and prospective clinical studies have also demonstrated associations between high levels of TF-positive MPs and VTE. 8, 9 There is ongoing interest to study TF and TF-positive MPs as potential predictive biomarkers in cancers with high risk of VTE. 10 .
Increased soluble P-selectin, a marker of platelet activation, has been shown to be associated with higher incidence of VTE.
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Increased endothelial expression of P-selectin appears to be important for CAT, possibly by promoting leukocyte adhesion. 7, 12 Plateletleukocyte interactions may also be important because neutrophil extracellular traps (NETs) can both promote platelet aggregation and activate the coagulation cascade. 13, 14 At least one ongoing clinical trial (NCT02285738) aims to examine the role of anti-platelet agents in the prevention of CAT.
| RISK FACTORS OF CANCER-ASSOCIATED THROMBOSIS
Many risk assessment models have been developed in attempt to identify patients with higher risk of CAT to strategize the optimal therapy. The Khorana Risk Score is one well-known tool that can help to assess the risks of first VTE in cancer patients undergoing treatment with chemotherapy. 15 
| PRIMARY PREVENTION OF THROMBOSIS IN CANCER PATIENTS

| Prevention of thrombosis in cancer patients undergoing surgery
Multiple randomized controlled trials have explored the role and optimal duration of thromboprophylaxis in cancer patients undergoing surgery.
A recent meta-analysis included 39 studies comparing perioperative pharmacological thromboprophylaxis in cancer patients undergoing surgery with no pharmacological prophylaxis (including mechanical prophylaxis or no prophylaxis), and demonstrated 50% reduction in the rate of deep vein thrombosis (DVT) with pharmacological prophylaxis, with an acceptable increase in the risk of bleeding, without a difference in mortality and pulmonary embolism (PE). 23 In addition, a systemic review and meta-analysis on seven randomized studies (encompassing 4807 patients) showed that extended thromboprophylaxis (2-6 weeks)
after an abdominopelvic cancer surgery significantly reduced the risk of all VTE and proximal DVT by approximately 50%, when compared with conventional duration of thromboprophylaxis (<2 weeks). 24 No difference was found in the incidence of symptomatic PE, major bleeding events, and 3-month all-cause mortality. 24 Given this evidence, pharmacological thromboprophylaxis is recommended for most cancer patients undergoing surgery, with extended prophylaxis (4 weeks) for patients undergoing abdominopelvic cancer surgery. with an oral agent would be less burdensome than LMWH.
| TREATMENT OF CANCER-ASSOCIATED THROMBOSIS
| Acute treatment (within 3-6 months)
Several pivotal randomized controlled studies have shaped our treatment strategy for CAT. In Tables 1 and 2 , we summarize and compare the key patient characteristics as well as clinical outcomes across major studies for the treatment of acute CAT (CLOT, CATCH, Hokusai VTE Cancer, Select-D, and DALTECAN studies).
| Low-molecular-weight heparin
Low-molecular-weight heparin (LMWH) has been the standard of care for treatment of acute CAT for at least 15 years, based on the results of several randomized controlled trials dedicated to patients with CAT. In these studies, LMWH was compared to vitamin K antagonists (VKA) for the treatment of acute VTE in cancer patients.
The pivotal CLOT study showed a significant reduction in VTE recurrence, 4 while three other smaller studies showed no difference in efficacy or safety outcomes, [30] [31] [32] and the most recent CATCH study 33 showed a nonsignificant reduction in VTE recurrence, but a significantly decreased risk of clinically relevant non-major bleeding (CRNMB) in the LMWH arm. We performed a meta-analysis of the summary data from these studies using Review Manager (RevMan) 
| Direct oral anticoagulants
Four DOACs have been approved for the treatment of DVT and/ or PE, including dabigatran, rivaroxaban, apixaban, and edoxaban.
All have demonstrated a comparable efficacy and safety to VKA in the cancer subpopulation. 37 However, the cancer subpopulation enrolled in these large studies was small and generally had lower risks of both recurrent VTE and hemorrhage when compared with patients enrolled in earlier studies specific to cancer patients (such as CLOT study to edoxaban experienced numerically fewer recurrent VTE events (7.9% vs 11.3%, P = .09) but more major bleeding events (6.9% vs 4.0%, P = .04) than those in the dalteparin group. However, the frequency of severe (fatal or potentially fatal) major bleeding, adjudicated without knowledge of treatment assignment and according to criteria defined a priori, was not different between the edoxaban and dalteparin groups. 46 The results of another study of this kind, the Select-D pilot trial, were also recently reported as in the abstract format. 47 A total of 406 cancer patients were randomized to rivaroxaban or dalteparin for the treatment of a proximal lower extremity DVT or PE. The primary endpoint-the 6-month VTE recurrence rate-was 3.9% in patients on rivaroxaban, as compared with 8.9% in patients on dalteparin; major bleeding occurred numerically more frequently with rivaroxaban (5.4% vs 3.0%). CRNMB also occurred more in the patients treated with rivaroxaban (12.3% vs 3.0%). More detailed data are awaited in the final publication.
A combined analysis of the two randomized trials was perfomend and a forest plot generated by using Review Manager Figure 2A ), but increase the risk of major bleeding (RR 1.74, 95% CI 1.05-2.88, Figure 2B ). 48 The majority of bleeds was gastrointestinal in origin, and the bleeding risk difference was most evident in patients with gastrointestinal cancer. The Hokusai VTE Cancer study showed that the severity of bleeds was less in patients treated with DOACs, with the majority bleeding events treated by transfusion only. Because the absolute risk difference for major bleeding is modest and severeity is less, we expect that many clinicians and patients will chose a DOAC rather than LMWH because of the 
F I G U R E 1 (A) Risk of recurrent venous thromboembolism in 6 months in randomized controlled trials of LMWH vs VKA (random effect model). (B) Risk of major bleeding in 6 months in randomized controlled trials of LMWH vs VKA (random effect model). CI, confidence interval; LMWH, low-molecular-weight heparin; M-H, Mantel-Haenszel; VKA, vitamin K antagonists
| Vitamin K antagonists
Vitamin K antagonists was shown to be less effective than LMWH in the prevention of recurrent cancer-associated VTE ( Figure 1A ). In addition, VKAs have disadvantages that include frequent laboratory monitoring and dose adjustment, multiple drug and diet interactions, and slow onset and offset. Therefore, VKA is not recommended as preferred treatment for CAT in major guidelines. However, it is still widely used in patients with CAT, given the relatively low cost, oral route, and high provider familiarity. A recent study using medical and pharmacy claims from a large insurance database showed that in 2940 cancer patients with a new VTE, the majority (47.7%) were initiated on warfarin as anticoagulation, while 25% on LWMH and 24.1% on rivaroxaban. 49 Based on the aggregate of available evidence, warfarin and other VKA should be a "third choice" for cancer patients, used only in situations where netiher a DOAC nor LMWH is feasible.
| Extended treatment (beyond 6 months)
The optimal duration and choice of anticoagulation beyond 6 months for CAT are not as well studied, as the duration of follow-up and anticoagulation treatment in previously cited pivotal studies were limited to 3-6 months. Outcomes beyond 6 months have been described in the DALTECAN study and in the TiCAT study, and both were single-arm cohort studies treating CAT patients with dalteparin (DALTECAN) or tinzaparin (TiCAT) for 12 months. 50, 51 Both studies showed that the risk of recurrent thrombosis or major bleeding is higher during the first 3-6 months, with an ongoing risk of recurrent thrombosis beyond 6 months. Therefore, major guidelines recommend continuing anticoagulation as long as risk factors (ongoing active malignancy and/or cancer treatment) for VTE are present.
The Hokusai VTE Cancer study followed enrolled patients for up to 12 months and demonstrated a continued risk of recurrent VTE beyond 6 months, supporting the practice of extended anticoagulation. The Select-D study initially designed a secondary phase after the initial 6 months of anticoagulation: to stop anticoagulation if there was no residual DVT on repeat ultrasound, and to randomize patients to rivaroxaban or placebo in patients who did have residual DVT. 47 However, this phase of the study was prematurally terminated because of slow recruitment.
As for the optimal type of anticoagulation for extended treatment of VTE in the cancer population, the recent Hokusai VTE Cancer study is the first large randomized study that followed anticoagulated cancer patients beyond 6 months, and showed that, based on a composite endpoint of recurrent VTE or major bleeding, edoxaban was not inferior to dalteparin during this timeframe. Therefore, edoxaban (and other DOACs, pending additional evidence) may be an attractive alternative to LMWH for extended treatment in patients with CAT. Future studies should test the hypothesis that lower doses of anticoagulation might be effective after some intial period of therapeutic anticoagulation. The STEP-CAT study (NCT 027526047) is an ongoing multi-center, open-label, single-arm study of enoxaparin 40 mg subcutaneously daily for patients with CAT who have completed 3-6 months of therapeutic anticoagulation.
| Treatment in special populations
| Patients with recurrent VTE while on anticoagulation
Cancer patients often develop recurrent VTE despite anticoagulation. However, there is no high-quality evidence to guide practice in this situation. Recommendations from major guidelines including changing oral anticoagulants to LMWH or escalating LMWH doses by 20%-25% are based on limited retrospective studies. [52] [53] [54] The results of a registry study addressing this issue were reported recently, including 212 cancer patients with recurrent VTE on anticoagulation. 55 
| Patients with thrombocytopenia
Cancer patients commonly have thrombocytopenia, either related to the underlying malignancy or to the cancer treatment. 56 ing it difficult to know which approach is best. There is certainly a need for larger and higher quality studies to address this common problem.
| Patients with brain tumors
Patients with brain tumors, either primary or metastatic, are at high risk of both thrombotic and bleeding complications, and therefore the optimal management is difficult and controversial. 
| Catheter-related thrombosis
The incidence of catheter-related thrombosis (CRT) in cancer patients varies widely, with more recent studies showing a rate of close to 20% when both symptomatic and asymptomatic events are included. 65 Primary thromboprophylaxis has not been shown to be beneficial and therefore is not routinely recommended. 66 At least one cohort study of cancer patients with catheter-associated thrombosis suggests that many patients can be treated with anticoagulation and leaving the catheter in place. 67 The optimal type and duration of anticoagulation are unclear. Guidelines usually recommend to continue anticoagulation as long as the catheter is in place and to use LMWH as preferred agents, extending from the standard of care for CAT as discussed above. 66, 68 However, the optimal duration of anticoagulation after catheter removal remains unknown given the lack of literature. The CATHETER study enrolled 74 patients with CRT treated with dalteparin bridged to warfarin. At 3 months, the risk of major bleeding was 4% with no recurrent VTE, with a line preservation rate of 100%. 67 The CATHETER 2 study further explored the use of DOAC in this condition. They treated 70 cancer patients and CRT with rivaroxaban, and found that at 12 weeks, the line preservation rate was 100%, with a rate of recurrent VTE of 1.43% and a major bleeding rate of 10%. 44 Both studies were single arm intervention without controls, and cross trial comparisons cannot be made.
| Incidental cancer-related thrombosis
Cancer patients frequently receive staging scans, and it is estimated that approximately 3% of cancer patients can have incidental PE on routine imaging. 69 Several retrospective or observational studies have indicated that the natural course of an incidental PE is comparable to a symptomatic one in terms of recurrence rate and survival. 70, 71 Therefore, standard anticoagulation is generally recommended for incidental PE in cancer patients. 72 To address this important issue, the Hokusai VTE Cancer study and Select-D trial are the first two large prospective studies including patients with incidental VTE (32.5% and 53% of enrolled patients, respectively) ( Table 1 ).
Subgroup analyses of these patients will be forthcoming; however, for now, guidelines suggest that incidental PE in cancer patients be treated with therapeutic anticoagulation, with the possible exception of isolated subsegmental PE. 
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